Logo image of CLLS

CELLECTIS - ADR (CLLS) Stock Fundamental Analysis

NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD

1.498  -0.03 (-2.09%)

Premarket: 1.5 +0 (+0.13%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CLLS. CLLS was compared to 571 industry peers in the Biotechnology industry. The financial health of CLLS is average, but there are quite some concerns on its profitability. CLLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLLS has reported negative net income.
In the past year CLLS had a positive cash flow from operations.
CLLS had negative earnings in each of the past 5 years.
CLLS had a negative operating cash flow in each of the past 5 years.
CLLS Yearly Net Income VS EBIT VS OCF VS FCFCLLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

CLLS has a better Return On Assets (-22.55%) than 74.51% of its industry peers.
With a Return On Equity value of -61.78%, CLLS perfoms like the industry average, outperforming 59.00% of the companies in the same industry.
Industry RankSector Rank
ROA -22.55%
ROE -61.78%
ROIC N/A
ROA(3y)-33.58%
ROA(5y)-27.97%
ROE(3y)-86.97%
ROE(5y)-64.54%
ROIC(3y)N/A
ROIC(5y)N/A
CLLS Yearly ROA, ROE, ROICCLLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLLS Yearly Profit, Operating, Gross MarginsCLLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLLS has more shares outstanding
The number of shares outstanding for CLLS has been increased compared to 5 years ago.
The debt/assets ratio for CLLS is higher compared to a year ago.
CLLS Yearly Shares OutstandingCLLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CLLS Yearly Total Debt VS Total AssetsCLLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

CLLS has an Altman-Z score of -1.67. This is a bad value and indicates that CLLS is not financially healthy and even has some risk of bankruptcy.
CLLS has a Altman-Z score (-1.67) which is in line with its industry peers.
CLLS has a debt to FCF ratio of 2.12. This is a good value and a sign of high solvency as CLLS would need 2.12 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.12, CLLS belongs to the best of the industry, outperforming 95.01% of the companies in the same industry.
CLLS has a Debt/Equity ratio of 0.65. This is a neutral value indicating CLLS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.65, CLLS is not doing good in the industry: 77.72% of the companies in the same industry are doing better.
Although CLLS does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.12
Altman-Z -1.67
ROIC/WACCN/A
WACC6.42%
CLLS Yearly LT Debt VS Equity VS FCFCLLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 1.92 indicates that CLLS should not have too much problems paying its short term obligations.
CLLS's Current ratio of 1.92 is on the low side compared to the rest of the industry. CLLS is outperformed by 78.25% of its industry peers.
CLLS has a Quick Ratio of 1.92. This is a normal value and indicates that CLLS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.92, CLLS is doing worse than 76.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
CLLS Yearly Current Assets VS Current LiabilitesCLLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.35%, which is quite impressive.
The Revenue has grown by 47.81% in the past year. This is a very strong growth!
The Revenue for CLLS have been decreasing by -15.57% on average. This is quite bad
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)47.81%
Revenue growth 3Y-46.36%
Revenue growth 5Y-15.57%
Sales Q2Q%997.93%

3.2 Future

CLLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.75% yearly.
CLLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 49.22% yearly.
EPS Next Y60.81%
EPS Next 2Y20.13%
EPS Next 3Y25.75%
EPS Next 5YN/A
Revenue Next Year169.93%
Revenue Next 2Y73.21%
Revenue Next 3Y15.73%
Revenue Next 5Y49.22%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLLS Yearly Revenue VS EstimatesCLLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
CLLS Yearly EPS VS EstimatesCLLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -1 -2 -3 -4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLLS Price Earnings VS Forward Price EarningsCLLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

CLLS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CLLS is cheaper than 99.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.02
EV/EBITDA N/A
CLLS Per share dataCLLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CLLS's earnings are expected to grow with 25.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.13%
EPS Next 3Y25.75%

More info and screens

0

5. Dividend

5.1 Amount

CLLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTIS - ADR

NASDAQ:CLLS (2/24/2025, 8:22:40 PM)

Premarket: 1.5 +0 (+0.13%)

1.498

-0.03 (-2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)04-28 2025-04-28/amc
Inst Owners20.91%
Inst Owner Change-96.21%
Ins Owners3.88%
Ins Owner ChangeN/A
Market Cap149.94M
Analysts86.15
Price Target5.61 (274.5%)
Short Float %0.3%
Short Ratio1.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.81%
Min EPS beat(2)6.42%
Max EPS beat(2)123.21%
EPS beat(4)3
Avg EPS beat(4)13.26%
Min EPS beat(4)-95.8%
Max EPS beat(4)123.21%
EPS beat(8)5
Avg EPS beat(8)9.17%
EPS beat(12)8
Avg EPS beat(12)12.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)74.43%
Min Revenue beat(2)50.31%
Max Revenue beat(2)98.54%
Revenue beat(4)2
Avg Revenue beat(4)2.07%
Min Revenue beat(4)-76.23%
Max Revenue beat(4)98.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.22%
EPS NQ rev (1m)-23.75%
EPS NQ rev (3m)-23.75%
EPS NY rev (1m)18.83%
EPS NY rev (3m)-0.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)31.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.4
P/FCF 3.02
P/OCF 2.91
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)0.5
FCFY33.11%
OCF(TTM)0.51
OCFY34.34%
SpS0.28
BVpS1.48
TBVpS1.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.55%
ROE -61.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 178.72%
ROA(3y)-33.58%
ROA(5y)-27.97%
ROE(3y)-86.97%
ROE(5y)-64.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.65
Debt/FCF 2.12
Debt/EBITDA N/A
Cap/Depr 9.74%
Cap/Sales 6.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -1.67
F-Score4
WACC6.42%
ROIC/WACCN/A
Cap/Depr(3y)46.06%
Cap/Depr(5y)230.5%
Cap/Sales(3y)24.1%
Cap/Sales(5y)60.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y60.81%
EPS Next 2Y20.13%
EPS Next 3Y25.75%
EPS Next 5YN/A
Revenue 1Y (TTM)47.81%
Revenue growth 3Y-46.36%
Revenue growth 5Y-15.57%
Sales Q2Q%997.93%
Revenue Next Year169.93%
Revenue Next 2Y73.21%
Revenue Next 3Y15.73%
Revenue Next 5Y49.22%
EBIT growth 1Y-5.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y141.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y146.1%
OCF growth 3YN/A
OCF growth 5YN/A